Oncotarget

Research Papers:

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

Yanlong Yang, Zaoxiu Hu, Yongchun Zhou, Guangqiang Zhao, Yujie Lei, Guangjian Li, Shuai Chen, Kai Chen, Zhenghai Shen, Xiao Chen, Peilin Dai and Yunchao Huang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:90197-90214. https://doi.org/10.18632/oncotarget.21644

Metrics: PDF 562 views  |   HTML 929 views  |   ?  


Abstract

Yanlong Yang1,*, Zaoxiu Hu2,*, Yongchun Zhou3,4,5,*, Guangqiang Zhao1, Yujie Lei1, Guangjian Li1, Shuai Chen1, Kai Chen1, Zhenghai Shen1, Xiao Chen1, Peilin Dai6 and Yunchao Huang1,3,4,5

1Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming 650118, PR China

2Department of Pathology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming 650118, PR China

3Cancer Research Institute of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming 650118, PR China

4Key Laboratory of Lung Cancer Research of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming 650118, PR China

5International Joint Laboratory of High Altitude Regional Cancer of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University(Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming 650118, PR China

6Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming 650118, PR China

*These authors have contributed equally to this work

Correspondence to:

Yunchao Huang, email: hycyn2008@163.com

Keywords: lung cancer, circulating microRNAs, diagnostic value, meta-analysis

Received: July 03, 2017     Accepted: August 17, 2017     Published: October 04, 2017

ABSTRACT

Many studies have investigated the diagnostic role of circulating microRNAs (miRNAs) in patients with lung cancer; however, the results still remain inconclusive. An updated system review and meta-analysis was necessary to give a comprehensive evaluation of diagnostic role of circulating miRNAs in lung cancer. Eligible studies were searched in electronical databases. The sensitivity and specificity were used to plot the summary receiver operator characteristic (SROC) curve and calculate the area under the curve (AUC). The between-study heterogeneity was evaluated by Q test and I2 statistics. Subgroup analyses and meta-regression were further performed to explore the potential sources of heterogeneity. A total of 134 studies from 65 articles (6,919 patients with lung cancer and 7,064 controls) were included for analysis. Overall analysis showed that circulating miRNAs had a good diagnostic performance in lung cancers, with a sensitivity of 0.83, a specificity of 0.84, and an AUC of 0.90. Subgroup analysis suggested that combined miRNAs and Caucasian populations may yield relatively higher diagnostic performance. In addition, we found serum might serve as an ideal material to detecting miRNA as good diagnostic performance. We also found the diagnostic role of miRNAs in early stage lung cancer was still relatively high (the sensitivity, specificity and an AUC of stage I/II was 0.81, 0.82 and 0.88; and for stage I, it was 0.80, 0.81, and 0.88). We also identified a panel of miRNAs such as miR-21-5p, miR-223-3p, miR-155-5p and miR-126-3p might serve as potential biomarkers for lung cancer. As a result, circulating miRNAs, particularly the combination of multiple miRNAs, may serve as promising biomarkers for the diagnosis of lung cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21644